Dr Clare Murray join us as a drug discovery consultant

At River BioMedics we are privileged to have Dr Clare Murray join us as a drug discovery consultant. Clare is advising us on our lead programme looking at a small molecule, disease modifying approach to heart failure with preserved ejection fraction.  

Clare has over 30 years’ experience in Drug Discovery and Development having worked in the Respiratory and Inflammation, Oncology and Emerging Innovations disease areas in AstraZeneca before joining C4X Discovery. Clare was Senior VP Drug Discovery at C4X Discovery, leading the biology teams and co-managing the research and development pipeline. She played a key role in the out licensing of the Orexin-1 receptor antagonist project to Indivior, and the partnering of the IL-17 inhibitor programme with Sanofi and the Nrf2 activator programme with AstraZeneca.

As Associate Director and Project Leader at AstraZeneca she provided leadership of cross-functional small molecule and biological drug discovery projects and supported development projects up to Phase 2 clinical studies. Clare was also involved in establishing the AstraZeneca Open Innovation platform and in managing academic industry partnerships.

Clare has published more than 20 scientific papers, has a PhD in Neuropharmacology and a first-class Biochemistry degree from the University of Kent, and is a Fellow of the British Pharmacological Society.